NCT02111551

Phase I Nicotinic Agonist Treatment Trial for Autism

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus and may help us to find new types of treatment for autism spectrum disorder. Subjects will come in for a screening visit and three more drug visits. There will be at least one week between each drug visit to allow the drug to be eliminated from your system completely. During each drug visit subjects will receive either a placebo (a capsule that looks like medicine but is not real), 75 mg of DMXB-A, or 150 mg of DMXB-A. During the drug day vital signs and well being will be monitored by the study physician. Subjects will complete some paper and pencil tasks to test memory, attention, speed, and problem solving, some rating scales and questionnaires, and the study team will record brain wave patterns with an electroencephalogram (EEG) .

Conditions

• Autism

Interventions

Type	Name	Description
DRUG	DMXB-A 150 mg
OTHER	placebo
DRUG	DMXB-A 75 mg

Timeline

• Start date: 2015-06-01
• Primary completion: 2016-05-01
• Completion: 2016-05-01
• First posted: 2014-04-11
• Last updated: 2016-06-16

Locations

1 site across 1 country: United States